Deutsche Bank raised the firm’s price target on Praxis Precision (PRAX) to $303 from $270 and keeps a Buy rating on the shares. The company announced a “double whammy of positive news,” the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines: Strong Buy Rating Backed by Regulatory Clarity and Positive Trial Results
- Praxis Precision price target raised to $83 from $77 at Wedbush
- Praxis Precision Medicines: Buy Rating Affirmed on Regulatory Milestones and Promising Pipeline Developments
- Praxis Precision price target raised to $499, named 2026 top pick at BTIG
- Praxis Precision price target raised to $340 from $258 at H.C. Wainwright